Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

COVID-19

Displaying 1 to 10 of 37 Posts . Displaying 10 of Posts . Page of 4 . Go To Page: . Per Page: . . . View All Sort By: .

Update on PsoProtect Registry Data

Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases.

Read More

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.

Professor Francesca Capon provides a commentary An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%.

Read More

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

n a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.

Read More

Commentary: NPF COVID-19 Task Force Guidance Statements

Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.

Read More

IPC Statement on SARS-CoV-2 Vaccines and Psoriasis

While the news of a potential SARS-CoV-2 vaccine is to be welcomed, the impact of psoriasis therapy, particularly systemic therapy, on the effectiveness and safety of vaccines needs to be considered.

Read More

Commentary: Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

Commentary provided on this international moderate-severe psoriasis case series, where biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding.

Read More

Global registry-based study reveals biologics use is associated with lower risk of COVID-19-related hospitalizations

According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.

Read More

PsoProtect registry data on first 200 cases

PsoProtect, the global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data so that it now includes the first 200 cases.

Read More

Commentary: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease

IPC Founding President Alan Menter and IPC Councilor Ulrich Mrowietz discuss the new guidance on psoriasis care from the National Psoriasis Foundation COVID-19 Task Force.

Read More

Declaración sobre el brote de coronavirus

Declaración del IPC sobre COVID y psoriasis La pandemia de SARS-CoV-2 continúa siendo una preocupación sanitaria de gravedad a nivel global. Desde que el Consejo Internacional de Psoriasis (IPC) publicó su declaración sobre COVID-19 el 11 de marzo, el coronavirus continúa propagándose rápidamente y actualmente constituye un peligro sanitario preponderante en todos los países de ingresos económicos altos, medios y bajos.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK